Developing
next-generation
biomolecular medicines
Sutura is advancing the field of biomolecular medicine through its peptide-based, Drug Conjugate Platform, improving the efficacy and safety of a broad range of biomolecular medicines.
Developing
next-generation
biomolecular medicines
Sutura is advancing the field of biomolecular medicine through its peptide-based, Drug Conjugate Platform, improving the efficacy and safety of a broad range of biomolecular medicines.
Overcoming the limitations of genetic and biomolecule-based medicines
At Sutura, we design Cell Penetrating Peptides to treat diseases that cannot be treated by conventional small molecules but require specialised, large biomolecules to interact specifically and effectively with the disease target.
Sutura Therapeutics is a biopharmaceutical company dedicated to advancing the field of biomolecular medicine through its peptide-based Drug Conjugate Platform
Overcoming the limitations of traditional biomolecule-based medicines
Sutura’s Drug Conjugate Platform leverages synthetic biomolecules, high payload delivery, and hypoimmunogenic technologies to author the next generation of biomolecular medicines.
At Sutura, we design Cell Penetrating Peptides (CPPs), which are synthetic biomolecules consisting of a specially designed peptide domain and an active biomolecular domain specific to the targeted disease. CPPs are designed to treat diseases that cannot be treated by conventional small molecules but require specific biomolecules to interact effectively with the disease target.
Separating technology development from product development
Recognising that technology and product development in the biotech industry have unique demands, encompassing talent, timelines, costs, and cultures, Sutura has made a deliberate decision to prioritise technology development.
Our Drug Conjugate Platform is being developed in a disease-area agnostic manner, with the aim of producing large therapeutic biomolecules capable of addressing a wide range of indications. By emphasising technology development, Sutura is poised to deliver cutting-edge solutions that can drive advancements in patient care.
Our technology
Learn more about Sutura’s Drug Conjugate Platform and how it sets Sutura apart from others in the field of biomolecular medicine.
Our team
At the core of Sutura’s innovative approach are its people. Each member brings a unique blend of skill, passion and perspective to the team.
Drug discovery
Sutura’s Drug Conjugate Platform has the potential to address a broad range of indications. This part of the website is still in development.
Newsroom
Stay informed with the most recent updates from Sutura Therapeutics via our newsroom.
Discover how Sutura's groundbreaking research at BioTrinity 2024 is setting the stage for advances in healthcare and biotechnology.